Characterization of the Effect of Hepatic Impairment on Upadacitinib Pharmacokinetics

Upadacitinib is a selective Janus kinase 1 inhibitor being developed for the treatment of several inflammatory autoimmune diseases, including rheumatoid arthritis. Upadacitinib is a nonsensitive substrate for metabolism by cytochrome P450 3A enzymes. This open‐label, single‐dose, multicenter study a...

Descripción completa

Detalles Bibliográficos
Autores principales: Trueman, Sheryl, Mohamed, Mohamed‐Eslam F., Feng, Tian, Lacerda, Ana Paula, Marbury, Thomas, Othman, Ahmed A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Special Populations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6766976/
https://www.ncbi.nlm.nih.gov/pubmed/30973649
http://dx.doi.org/10.1002/jcph.1414

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6766976/
https://www.ncbi.nlm.nih.gov/pubmed/30973649
http://dx.doi.org/10.1002/jcph.1414

Ejemplares similares